Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 3/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451989 | 0.88 | LMNA (0.36) | LMNATDP1SMN1; SMN2PDE4APDE4C | |
| SCHEMBL12330441 | 0.86 | LMNA (0.33) | LMNATDP1SMN1; SMN2PDE4APDE4C | |
| SCHEMBL13998050 | 0.81 | HSD17B10 (0.34) | LMNATDP1HSD17B10CA1CA2 | |
| SCHEMBL152920 | 0.76 | KDM4E (0.42) | LMNASMN1; SMN2PDE4APDE4CPDE4D | |
| SCHEMBL20243530 | 0.74 | CA1 (0.38) | SMN1; SMN2PDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL7384969 | 0.74 | KMT2A (0.41) | LMNASMN1; SMN2PDE4APDE4CPDE4D | |
| SCHEMBL941919 | 0.74 | PDE4A (0.37) | SMN1; SMN2PDE4APDE4CPDE4DALDH1A1 | |
| SCHEMBL5665844 | 0.72 | ALOX15 (0.50) | LMNASMN1; SMN2PDE4DHSD17B10ALDH1A1 | |
| SCHEMBL14927093 | 0.72 | PDE4A (0.37) | PDE4APDE4CPDE4DCA1CA2 | |
| SCHEMBL1314787 | 0.71 | PDE4A (0.41) | SMN1; SMN2PDE4APDE4CPDE4DCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005728-A1 | SUBSTITUTED PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005728-A1 | SUBSTITUTED PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005728-A1 | SUBSTITUTED PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR, PTGDR2, PTGER2 | LMNA 4374/4885TDP1 2234/4885SMN1; SMN2 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.